Business
Wellbeing Subsidiary KGK Science Enters Into Research Contract With Halucenex for Phase II Clinical Trial
Wellbeing Subsidiary KGK Science Enters Into Research Contract With Halucenex for Phase II Clinical Trial.
About this update from Wellbeing Digital Sciences Inc.
[{"type":"text","content":"\nWellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has entered into a research services agreement with Halucenex Life Sciences Inc. (“Halucenex”), a psychedelic subsidiary of Creso Pharma (ASX:CPH, OTC:COPHF, FRA:1X8).\n\n“We are thrilled to be working with Halucenex for their planned phase II clinical trials to test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD). Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets,” commented Najla Guthrie, CEO of Wellbeing and KGK. “This marks and important step in moving the industry that much closer to creating alternative medicines for a growing population base.”\n\nUnder the research and services agreement with Halucenex, KGK will perform research services, including the development of the clinical trial protocol, preparations towards the Phase II clinical trials, data management and validation, statistical analysis and drafting of the final report (“Services”).\n\n“KGK is a leading contract research organization (CRO), offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries,” added Bill Flemming, CEO and Founder of Halucenex. “We are confident that KGK’s role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions.”\n\nABOUT KGK SCIENCE\n\nSubsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical...